{
    "root": "556a7d5f-2c3c-4efb-ac0c-fca140791602",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Etodolac",
    "value": "20250324",
    "ingredients": [
        {
            "name": "ETODOLAC",
            "code": "2M36281008"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHYLCELLULOSE (100 MPA.S)",
            "code": "4GFU244C4J"
        },
        {
            "name": "POLYETHYLENE GLYCOL 1600",
            "code": "1212Z7S33A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "carefully consider potential benefits risks etodolac treatment options deciding etodolac . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . etodolac tablets , usp indicated : •for acute long-term management signs symptoms following : 1.osteoarthritis 2.rheumatoid arthritis •for management acute pain",
    "contraindications": "carefully consider potential benefits risks etodolac treatment options deciding etodolac . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy etodolac , dose frequency adjusted suit individual patient 's needs . adjustment etodolac generally required patients mild moderate renal impairment . etodolac used caution patients , , nsaids , may decrease renal function patients impaired renal function ( ) .",
    "warningsAndPrecautions": "etodolac tablets , usp available : 400 mg tablets ( white off-white , oval , unscored , film-coated tablets , imprinted `` apo 041 `` one side `` 400 `` side . ) -in bottles 20 , ndc 68788-8846-2 -in bottles 30 , ndc 68788-8846-3 -in bottles 60 , ndc 68788-8846-6 -in bottles 90 , ndc 68788-8846-9 -in bottles 100 , ndc 68788-8846-1 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container [ usp ] . dispense medication guide available https : //www.apotex.com/products/us/mg.asp apotex inc. etodolac tablets , usp 400 mg 500 mg manufactured apotex inc. toronto , ontario canada m9l 1t9 manufactured apotex corp. weston , florida usa , 33326 revised : august 2024 rev . 10 repackaged : preferred pharmaceuticals inc .",
    "adverseReactions": "etodolac contraindicated patients known hypersensitivity etodolac . etodolac given patients experienced asthma , urticaria , allergic-type taking aspirin nsaids . severe , rarely fatal , anaphylactic-like nsaids reported patients ( , pre-existing asthma ) . •etodolac tablets contraindicated setting coronary artery bypass graft ( cabg ) surgery ( ) .",
    "indications_original": "Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS\n                     ). \n                  Etodolac tablets, USP are indicated:\n                  \n                     \n                        •For acute and long-term use in the management of signs and symptoms of the following:\n                           \n                              1.Osteoarthritis \n                           \n                              2.Rheumatoid arthritis \n                        \n                     \n                     \n                        •For the management of acute pain",
    "contraindications_original": "Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS\n                     ). \n                  After observing the response to the initial therapy with etodolac, the dose and frequency should be adjusted to suit an individual patient's needs. \n                  Dosage adjustment of etodolac is generally not required in patients with mild to moderate renal impairment. Etodolac should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function (see ).",
    "warningsAndPrecautions_original": "Etodolac Tablets, USP are available as:\n                  400 mg Tablets (White to off-white, oval, unscored, film-coated tablets, imprinted \"APO 041\" on one side and \"400\" on the other side.)\n                  -in bottles of 20, NDC 68788-8846-2\n                  -in bottles of 30, NDC 68788-8846-3\n                  -in bottles of 60, NDC 68788-8846-6\n                  -in bottles of 90, NDC 68788-8846-9\n                  -in bottles of 100, NDC 68788-8846-1\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].  \n                  Dispense in a tight, light-resistant container [see USP].\n                  Dispense with Medication Guide available at https://www.apotex.com/products/us/mg.asp\n                  \n                  \n                     APOTEX INC. \n                     \n                     ETODOLAC TABLETS, USP \n                     \n                     400 mg and 500 mg\n                  \n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Manufactured by\n                              \n                               Apotex Inc.\n                              Toronto, Ontario\n                              Canada M9L 1T9\n                           \n                           \n                              \n                                 Manufactured for\n                              \n                              Apotex Corp.\n                              Weston, Florida\n                              USA, 33326\n                           \n                        \n                     \n                  \n                  Revised: August 2024\n                  Rev. 10\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions_original": "Etodolac is contraindicated in patients with known hypersensitivity to etodolac. \n                  Etodolac should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see and \n                        PRECAUTIONS, \n                        \n                           Pre-existing Asthma\n                        \n                     ). \n                  \n                     \n                        •Etodolac tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see \n                           WARNINGS\n                        )."
}